<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200608047697N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-05-16</date_registration>
      <primary_sponsor>Kermanshah University of Medical Sciences</primary_sponsor>
      <public_title>Investigating effect of anti-inflammatory, portfolio low carbohydrate, and intermittent fasting on improving pre- diabetes</public_title>
      <acronym></acronym>
      <scientific_title>The effect of anti-inflammatory, portfolio low carbohydrate, and intermittent fasting on cardio- metabolic status and gene expression in subject with pre-diabetes; an open label randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-07-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/76653</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Participants will be randomly divided into 4 groups using a random number table: 1) calorie restriction (control) (n=25), 2) low carbohydrate portfolio diet group (n=25), 3) intermittent fasting group (n= 25) and 4) the anti-inflammatory diet group (n=25).</study_design>
      <phase>3</phase>
      <hc_freetext>pre- diabetes.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: anti-inflammatory diet- Diet characteristics: 1. Restriction of daily calorie intake (75% of daily energy requirement). 2. Variety with sufficient amounts of fresh foods, minimum amount of processed foods and fast foods, 3. Abundant amounts of fruits and vegetables with a limit on daily calorie intake - The desired diet is provided to patients in the form of a meal plan along with nutrition counseling every month. . Intervention 2: Intervention group: portfolio low carbohydrate diet- Diet characteristics: this diet emphasizes 4 components: soluble fiber, nuts, soybeans, and fatty acids with a double bond (MUFA), which distribution of macronutrients is as follows: 40% fat, carbohydrates 40%, 20% protein, daily calorie restriction - The desired diet is provided to patients in the form of a meal plan along with nutrition counseling every month. Intervention 3: Intervention group: intermittent fasting diet- Diet characteristics: 5:2 diet, 2 days a week: 500 to 600 kcal per day (breakfast 100 kcal, lunch and dinner 250 kcal each) - 5 days a week: 2000 kcal - The desired diet is provided to patients in the form of a meal plan along with nutrition counseling every month. Intervention 4: Control group: Calorie restriction diet- Diet characteristics: restriction of daily calorie intake (75% of daily energy requirement) and carbohydrate distribution: breakfast: 15%, snack: 13%, lunch: 24%, snack: 13%, dinner: 24%, late night: 11% - The desired diet is provided to patients in the form of a meal plan along with nutrition counseling every month.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shima Moradi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Isar Sq., next to Farabi Education and Treatment Center, Faculty of Nutritional Sciences and Food Technology, Kermanshah, Iran.</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6719851552</zip>
        <telephone>+98 83 3710 2015</telephone>
        <email>shima.moradi1400@yahoo.com</email>
        <affiliation>Kermanshah University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Shima Moradi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Isar Sq., next to Farabi Education and Treatment Center, Faculty of Nutritional Sciences and Food Technology, Kermanshah, Iran.</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6719851552</zip>
        <telephone>+98 83 3710 2015</telephone>
        <email>shima.moradi1400@yahoo.com</email>
        <affiliation>Kermanshah University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 18-55 years
BMI ≥25 kg/m2
Consent to participate in the study
Suffering from pre-diabetes according to ADA criteria (hemoglobin A1c level between 5.7 and 6.4% or FBS level between 100-125 mg/dL)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>55 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy and lactation
Suffering from diseases such as autoimmune diseases, thyroid and unstable cardiovascular diseases, diabetes, severe depression (due to the inability to answer questions), mental and psychological diseases
Medication use related to the above conditions</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: anti-inflammatory diet- Diet characteristics: 1. Restriction of daily calorie intake (75% of daily energy requirement). 2. Variety with sufficient amounts of fresh foods, minimum amount of processed foods and fast foods, 3. Abundant amounts of fruits and vegetables with a limit on daily calorie intake - The desired diet is provided to patients in the form of a meal plan along with nutrition counseling every month. .</i_keyword>
      <i_keyword>Intervention group: portfolio low carbohydrate diet- Diet characteristics: this diet emphasizes 4 components: soluble fiber, nuts, soybeans, and fatty acids with a double bond (MUFA), which distribution of macronutrients is as follows: 40% fat, carbohydrates 40%, 20% protein, daily calorie restriction - The desired diet is provided to patients in the form of a meal plan along with nutrition counseling every month.</i_keyword>
      <i_keyword>Intervention group: intermittent fasting diet- Diet characteristics: 5:2 diet, 2 days a week: 500 to 600 kcal per day (breakfast 100 kcal, lunch and dinner 250 kcal each) - 5 days a week: 2000 kcal - The desired diet is provided to patients in the form of a meal plan along with nutrition counseling every month.</i_keyword>
      <i_keyword>Control group: Calorie restriction diet- Diet characteristics: restriction of daily calorie intake (75% of daily energy requirement) and carbohydrate distribution: breakfast: 15%, snack: 13%, lunch: 24%, snack: 13%, dinner: 24%, late night: 11% - The desired diet is provided to patients in the form of a meal plan along with nutrition counseling every month.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Improving glycemic indices and related gene expression including insulin Receptor (INSR), transcription factor 7 like 2 (TCF7L2), PPARG Co-activator 1- α (PGC1-a). Timepoint: All measurements will be done at the beginning of the study (before the intervention) and at the end of the study (after the intervention). Method of measurement: Glycemic indices including insulin level, blood sugar, hemoglobin A1c will be evaluated in the central laboratory of the University of Medical Sciences. The expression of the mentioned genes is determined by Real Time PCR method and specific primers designed with reliable software.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Anthropometric indices and body composition. Timepoint: Before the intervention, in the middle of the study (end of week 6), after the intervention. Method of measurement: Anthropometric measurements include height, weight, waist circumference. Height will be measured in a standing position without shoes. Measurement of waist circumference in the narrowest area, the distance between the bottom of the last rib and the top of the pubic bone in exhalation, is done using an inflexible tape measure without bearing any pressure on the person's body with an accuracy of 0.1 cm. Accurate assessment of weight and body composition is done by the body composition analysis device (Jawon Medical Plus model Avis 333) available in the research laboratory of the school of Nutritional Sciences and Food Technology. Body mass index (BMI) will be calculated by dividing weight (kilograms) by the square of height (meters).</sec_outcome>
      <sec_outcome>Blood pressure. Timepoint: Before the intervention, in the middle of the study (end of week 6), after the intervention. Method of measurement: A digital arm sphygmomanometer will be used to measure people's blood pressure. At least half an hour before, people should not have intense activity, they should not have consumed coffee, tea and cigarettes. For this purpose, the participant will be asked to sit on an armchair for 5 minutes before the measurement. Then we will measure the person's blood pressure from the left arm twice at 15 minutes intervals. Finally, we will record the average blood pressure measured.</sec_outcome>
      <sec_outcome>C reactive protein. Timepoint: before and after intervention. Method of measurement: It will be evaluated by the central laboratory of Kermanshah University of Medical Sciences.</sec_outcome>
      <sec_outcome>Lipid profile. Timepoint: before and after intervention. Method of measurement: It will be evaluated by the central laboratory of Kermanshah University of Medical Sciences.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kermanshah University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-04-23</approval_date>
        <contact_name>Ethics committee of Kermanshah University of Medical Sciences</contact_name>
        <contact_address>Kermanshah Province, Kermanshah, Beheshti Blvd, 83VX+PCM Kermanshah Kermanshah Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
